A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

NCT06081322 | Unknown Phase 1

• 1 other identifier: CISPD-5
• Study Type: interventional
• Target: 29
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a prospective, single-center, open, single-arm, exploratory study to evaluate the safety and efficacy of 177Lu-EB-FAPI PRRT, and to explore 177Lu-EB-FAPI in patients with advanced pancreatic cancer and cholangiocarcinoma. Eligible patients with advanced pancreatic cancer or cholangiocarcinoma were screened and enrolled after signing the informed consent forms. In the first stage of the enrolled patients, the 177Lu-EB-FAPI treatment dose was determined using a 3 + 3 dose escalation mode. Patients enrolled in the second phase, divided into pancreatic cancer cohort and cholangiocarcinoma based on pathology, will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles. The aim of the study is to evaluate the safety and efficacy of the 177Lu-EB-FAPI treatment.

Conditions

Advanced Pancreatic Cancer and Cholangiocarcinoma

Outcome Measures

Primary Outcomes (4)

• Safety of treatment：hematotoxicity

  Safety evaluation，Complete Blood Count was done continuously during treatment by using CTCAE 5.0 during study

  Up to 2 years.

• Objective reponse rate (ORR)

  The proportion of patients who had tumor evaluated as PR according to RECIST1.1 criteria during phase Ib

  Up to 2 years

• Safety of treatment：Hepatotoxicity

  Safety evaluation，liver function lab test was done continuously during treatment and the level of serum ALT, AST, and total bilirubin will be evaluated by using CTCAE 5.0 during study.

  Up to 2 years.

• Safety of treatment：renal toxicity

  Safety evaluation，renal function lab test was done continuously during treatment and the level of serum creatinine will be evaluated by using CTCAE 5.0 during study.

  Up to 2 years.

Secondary Outcomes (4)

• Disease control rate (DCR)

  Up to 2 years

• Duration of remission （DoR）

  Up to 2 years

• Progression-free survival （PFS）

  Up to 2 years

• Overall survival (OS)

  Up to 2 years

Study Arms (3)

Phase Ia: Dose escalation

EXPERIMENTAL

To determine the therapeutic dose of 177Lu-EB-FAPI using a 3 + 3 dose-escalation mode

Drug: PRRT with 177Lu-EB-FAPI

Phase Ib: Dose expansion-pancreatic cancer cohort

EXPERIMENTAL

In pancreatic cancer cohort, patients will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles.

Drug: PRRT with 177Lu-EB-FAPI

Phase Ib: Dose expansion-cholangiocarcinoma cohort

EXPERIMENTAL

In cholangiocarcinoma cohort, patients will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles.

Drug: PRRT with 177Lu-EB-FAPI

Interventions

PRRT with 177Lu-EB-FAPI DRUG

PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue

Phase Ia: Dose escalation; Phase Ib: Dose expansion-cholangiocarcinoma cohort; Phase Ib: Dose expansion-pancreatic cancer cohort

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed the informed consent form;
• Age: 18-75 years old (when signing the informed consent form);
• Received 68 Ga-FAPI 46 PET imaging positive before treatment;
• Phase Ia requires patients who have previously failed at least 2 lines of systemic chemotherapy or who the investigator considers unsuitable to receive systemic chemotherapy; Phase Ib Cohort 1, enrollment of patients with hist-or cytologically confirmed metastatic pancreatic cancer; Phase Ib Cohort 2, enrollment of patients with hist-or cytologically confirmed metastatic cholangiocarcinoma;
• Phase Ia requires at least one evaluable lesion confirmed per RECIST 1.1 criteria; Phase Ib requires at least one measurable lesion confirmed per RECIST 1.1 criteria;
• ECOG score 0-1, expected survival greater than 3 months;
• Major organs function well;
• Patients must have reliable contraception during the study and within 6 months after the study period; negative serum pregnancy / urine pregnancy test within 7 days before study enrollment and must be non-lactating subjects; male subjects should agree to have contraception during the study and within 6 months after the end of the study period.

You may not qualify if:

• Prior treatment before the first dose included chemotherapy and targeted therapy with any associated toxicity (CTCAE v5.0) of\> 1 N. A., excluding alopecia;
• Severe organ failure, such as respiratory failure, uncontrolled thyroid dysfunction including hyperthyroidism and hypothyroidism, or uncorrection of K +, Na +, Ca 2 + electrolyte disorders;
• Within 5 years, the patient had previous or both other malignant tumors (except for cured skin basal cell carcinoma and cervical carcinoma in situ); had other malignant tumors, but the following two conditions can be enrolled: other malignant tumors treated with single surgery with R0 resection and no recurrence and metastasis; cured cervical carcinoma in situ, skin basal cell carcinoma, nasopharyngeal carcinoma and superficial bladder tumor \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\];
• Major surgical treatment with significant traumatic injury within 28 days prior to the first medication;
• Long-term non-healed wound or fracture; Active bleeding or high risk of bleeding considered by the investigator, such as gastric fundus varices, hemoptysis, etc.;
• Motor / venous thrombosis events, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, occurred within 6 months before the first medication;
• Patients with a history of psychiatric substance abuse and unable to quit or with mental disorders;
• Symptomatic interstitial lung disease, and conditions that may cause drug pulmonary toxicity or associated pneumonia;
• Patients with any severe and / or uncontrolled disease.
• Previous history of severe allergy to macromolecular drugs, or allergy to the known component of 177Lu-EB-FAPI injection;
• Claustrophobic or radiologically phobic patients, or patients with mental disorders or primary affective disorders;
• According to the discretion of the investigator, subjects with a serious hazard to subject safety or concomitant illness affecting the study or other reasons for enrollment.

Sponsors & Collaborators

• Zhejiang University: lead

Study Sites (1)

First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, 310000, China

RECRUITING

MeSH Terms

Conditions

Cholangiocarcinoma

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Central Study Contacts

Tingbo Liang, PhD

CONTACT

+86 19941463683; liangtingbo@zju.edu.cn

Yiwen Chen, MD

CONTACT

+86 15088682641; cherry0705@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine

Study Record Dates

• First Submitted: June 12, 2023
• First Posted: October 13, 2023
• Study Start: September 1, 2023
• Primary Completion: June 30, 2024
• Study Completion: June 30, 2025
• Last Updated: October 13, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)